NAD+/SIRT1,NMNAKI

Zhaozhi Wen1,2, Jiazeng Wang1, Yihang Yang1

  • 1School of Life Sciences, Nantong Laboratory of Development and Diseases, Nantong University, Nantong, Jiangsu, China.

Frontiers in immunology
|February 20, 2026
PubMed
概括

尼古丁胺胺氨基二核酸 (NAD+) 前体β-尼古丁胺胺单核酸 (NMN) 在预防西斯普拉丁相关急性损伤 (CIS-AKI) 中显示出有前途. 通过激活NAD+-SIRT1通路,NMN可以减少损伤,炎症和氧化应激.